Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

• Status: Unknown status
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Huazhong University of Science and Technology
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

• Hypertension (2 grade)

Exclusion Criteria:

• Secondary hypertension

• Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor

• Pregnancy